Telix stock rises 4.31 percent to AUD 15.73 on October 16

Published on 10/17/2026 at 18:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached USD 477.00 million, up 22.00 percent year over year. Telix stock was AUD 15.73 on October 16, 2026, up 4.31 percent on the ASX.

Market move and valuation

Telix's ASX session ended on October 16, 2026.
First-half revenue reached USD 477.00 million, up 22.00 percent year over year.
Telix stock last traded at AUD 15.73 on October 16, 2026 at 4:10 p.m. AEDT, 4.31 percent above the ASX prior close.
Telix traded at a trailing P/E ratio of 122.70 on October 16, 2026.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix stock rose 4.31 percent on the ASX on October 16, 2026, reaching a last traded price of AUD 15.73. The session followed a first-half revenue increase of 22.00 percent to USD 477.00 million, a figure reported by Business News Australia.

Revenue gives the stock scale

Telix's first-half revenue was USD 477.00 million, compared with USD 390.00 million in the year-earlier period. The 22.00 percent increase was accompanied by positive net income of USD 41.00 million, compared with a USD 2.00 million loss in the first half of 2025, according to Business News Australia.

Price position after October 16

The ASX session opened at AUD 15.20, reached an intraday high of AUD 15.87 and touched a low of AUD 14.93. Volume was 1,267,192 shares against an average of 1,925,445 shares. Telix therefore finished 13.67 percent below its 52-week high of AUD 18.22 and 90.31 percent above its 52-week low of AUD 8.26, both as of October 16, 2026.

Valuation and upcoming dates

Telix had a market capitalization of AUD 5.3 billion and a trailing P/E ratio of 122.70 on October 16, 2026. The company is scheduled to present 20 abstracts at the European Association of Nuclear Medicine congress from October 17 to October 21, 2026, including studies in prostate, brain and renal cancers, according to PR Newswire.

Comparison with peers

Telix Pharmaceuticals: plus 4.31 percent, P/E 122.70, market capitalization AUD 5.3 billion
Novartis (NYSE, USD): plus 0.16 percent, P/E 23.09, market capitalization USD 286.3 billion
Eli Lilly and Company (NYSE, USD): plus 0.43 percent, P/E 42.18, market capitalization USD 1.2 trillion

ASX session leaves a wide range

Telix last traded at AUD 15.73 on the ASX on October 16, 2026 at 4:10 p.m. AEDT, 4.31 percent above the ASX prior close of AUD 15.08. The price remained below the 52-week high while valuation stayed far above the trailing multiples of the two large pharmaceutical peers listed above.